Skip Navigation
Menu Search
Sibley Memorial Hospital

In This Section      

Conditions We Treat

At Sibley Medical Center, we treat the four most common blood cancers.


Leukemia begins in the bone marrow, where blood production takes place. When you have leukemia, your body makes too many blood cells. These blood cells are abnormal, but unlike most cancers, they do not form tumors. Instead, they travel in the blood throughout the body, which means they can reach almost any organ, and can present itself in many different ways, depending on which organs are involved.


Lymphoma affects the lymphatic system’s white blood cells. It causes these cells, known as lymphocytes, to become abnormal and multiply. Lymphoma can affect people of nearly any age, from children and teens to older adults.

Hodgkin Lymphoma

Also known as Hodgkin’s Disease, this type of lymphoma usually begins in a lymph node in the chest or neck, producing a painless lump or swollen area. If it spreads, it tends to go to nearby lymph nodes. In the majority of cases, Hodgkin Lymphoma can be cured.

Non-Hodgkin Lymphoma

Although it also affects the lymphatic system, but it can start almost anywhere in the body. Non-Hodgkin lymphoma is unlike Hodgkin lymphoma because of the kinds of tumors it produces. Non-Hodgkin Lymphoma tumors are made up almost entirely of cancer cells.

Multiple Myeloma

Multiple myeloma affects a type of white blood cell called a plasma cell. Plasma cells produce antibodies to help fight infection and disease. In multiple myeloma, cancerous plasma cells (myeloma cells) are found in the bone marrow, the spongy tissue inside bones that manufactures blood cells. 

Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS) is a group of disorders in which the bone marrow produces too few mature and/or functioning red blood cells, white blood cells or platelets. It begins with a change to a normal stem cell in the bone marrow.  The overall incidence of MDS in the United States is estimated at close to four cases per 100,000 people, with as many as 20,000 to 30,000 people diagnosed annually.